DiabetesSeriesLive

CME Presentations

Current Advances in Insulin Therapy: Improving Skills for Clinical Care


Presentations


Speakers

  • Alissa Segal, PharmD, RPh, CDE, CDTC, FCCP

    Alissa Segal, PharmD, RPh, CDE, CDTC, FCCP

    Alissa Segal, PharmD, RPh, CDE, CDTC, FCCP

    Clinical Pharmacist and Diabetes Educator

    Alissa R. Segal, PharmD, RPh, CDE, CDTC, FCCP is an Associate Professor at MCPHS University and clinical pharmacist at the Joslin Diabetes Center, Boston, MA. After completing post-doctorate residencies at the Medical Center at Princeton and the Medical University of South Carolina, Dr. Segal taught for several years at the University of New Mexico. In 2007, she joined MCPHS University and established clinical pharmacy services at the Joslin. Her research focus on the care of adults with diabetes has led to numerous publications, on diabetes in older adults and concentrated insulin, and book chapters in the Joslin Deskbook, Endocrine and Metabolic Medical Emergencies, and Geriatric Diabetes. She was one of the first pharmacists to receive the Certified Diabetes Technology Clinician certification and is a fellow of the American College of Clinical Pharmacy (ACCP).
  • Richard Beaser, MD

    Richard Beaser, MD

    Richard Beaser, MD

    Senior Physician; Medical Director, Continuing Medical Education

    Richard S. Beaser, M.D., is a practicing physician in the Joslin Clinic and holds the position of Associate Clinical Professor of Medicine at Harvard Medical School. He has also been the Medical Executive Director of Professional Education at Joslin and was instrumental in developing that activity at Joslin, a department he founded in 1990. Dr. Beaser graduated in 1973 from Trinity College, Hartford, and received his medical degree from Boston University School of Medicine in 1977. He served as a resident in internal medicine at the University of Massachusetts Medical Center in Worcester from 1977-1980. He was a fellow in endocrinology at the Joslin Diabetes Center, Boston, MA 1980-81, and in Endocrinology at the Lahey Clinic Medical Center, Burlington, MA 1981-82. Dr. Beaser has been on the staff of the Joslin Diabetes Center since 1982. He has held numerous past positions at Joslin, including Section Chief of the Adult Diabetology Practice, Medical Director of the Diabetes Treatment Unit, Coordinator of the Patient Education Section, and Medical Director of Joslin TrialNet, a clinical trials network. He has been a clinical research investigator, including the landmark Diabetes Control and Complications Trial. Dr. Beaser has authored 4 books: Joslin Diabetes Manual, Outsmarting Diabetes, The Joslin Guide to Diabetes, and Joslin’s Diabetes Deskbook: A Guide for Primary Care Providers. Dr Beaser is a well-known national lecturer on clinical diabetes and its comorbidities. He is the author of numerous publications in peer review journals, review articles, and book chapters. In his role as Medical Executive Director of Professional Education at Joslin Diabetes Center, and currently as the Chair of the CME Committee, Dr. Beaser has a specific focus on development or oversight of educational content for the department, targeting physicians, other medical professionals, and patients. He leads departmental conceptualization and development of projects and activities.
  • Jason Gaglia, MD

    Jason Gaglia, MD

    Jason Gaglia, MD

    Director of Hood Center for the Prevention of Childhood Diabetes

    Jason Gaglia, MD, MMSc is Director of the Hood Center for Prevention of Childhood Diabetes at Joslin Diabetes Center and an Assistant Professor of Medicine at Harvard Medical School. He is a practicing adult endocrinologist at Joslin Clinic and Harvard Vanguard Medical Associates. Dr. Gaglia’s research interests include endocrine imaging and immunology of diabetes. He was previously a member of the clinical islet transplant team at the National Institute of Health. More recently he has led a team demonstrating noninvasive imaging of inflammation in the pancreas associated with the development of type 1 diabetes. Dr. Gaglia is an active member of the American Association of Clinical Endocrinologists (AACE). He is on the editorial board of Endocrine Practice, the official journal of AACE, and serves on several AACE committees.
  • Mark E. Molitch, MD

    Mark E. Molitch, MD

    Mark E. Molitch, MD

    Martha Leland Sherwin Professor of Endocrinology, Division of Endocrinology, Metabolism and Molecular Medicine

    Mark Molitch, M.D. is the Martha Leland Sherwin Professor of Medicine in the Division of Endocrinology, Metabolism and Molecular Medicine at the Northwestern University Feinberg School of Medicine. Prior to coming to Northwestern in 1984, Dr. Molitch was an Associate Professor at Tufts University School of Medicine in Boston, Massachusetts. Dr. Molitch has participated in clinical research for many years, focusing on diabetic kidney disease and other long-term complications of diabetes. He has been the PI for the Northwestern center of the Diabetes Control and Complications Trial (DCCT) and its follow-up study, the Epidemiology of Diabetes Interventions and Complications (EDIC) study, the Northwestern Center of the ongoing Diabetes Prevention Program Observational Study (DPPOS), the Northwestern center of the ongoing Prevention of Early Renal Loss (PERL) study in patients with type 1 diabetes, and was the Co-Principal Investigator for Northwestern center of Diabetes of the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D). He has also had a long-standing interest in the pathogenesis and treatment of pituitary tumors. Dr. Molitch has been active in the American Diabetes Association (ADA). He chaired the Professional Practice Committee that wrote the 2002 ADA”Standards of Medical Care for Patients with Diabetes Mellitus,” chaired the working group that wrote the ADA Position Statement “Diabetic Nephropathy,” and served as chair of the ADA’s Provider Recognition Program. He also chaired the Technical Expert Review Panel of the National Diabetes Quality Improvement Alliance. In addition to editing eight books and journal volumes, Dr. Molitch has authored or coauthored more than 450 original papers, review articles, book chapters, case reports and other publications. In 1997, Dr. Molitch was the recipient of the “Outstanding Physician Educator in the Field of Diabetes Award” by the American Diabetes Association and in 2013 was the recipient of the “Distinguished Educator Award” of The Endocrine Society. In 2006 he was elected to the Council of The Endocrine Society. He also completed a 3 year term as Chair of the Clinical Endocrinology Update Program of the Endocrine Society in 2012 and was President of the Pituitary Society in 2012-2013.

CME Information

Current Advances in Insulin Therapy: Improving Skills for Clinical Care


LEARNING OBJECTIVES

At the conclusion of this activity, participants will be able to:

The Rapidly Evolving Options for Insulin Therapy: Clinically-Focused Pharmacology

  • Identify clinically relevant pharmacokinetic and pharmacodynamic properties of the new and evolving insulins and insulin combinations
  • Identify indications for the initiation of insulin replacement therapy for people with T2DM
  • Select appropriate and individualized clinical options from among the various guideline-driven treatment pathways for insulin initiation and advancement

Physiologic Insulin Replacement: Strategies for Non-Specialist Diabetes Care Providers

  • Describe the indications for, and design and implementation process for, basal/bolus insulin replacement therapy, and the role of newer insulins and treatment tools in doing so
  • Select appropriate design and implementation processes for basal/bolus insulin replacement therapy, which incorporate the role of newer insulins and treatment tools
  • Recognize and identify clinical scenarios where the use of newer technology, such as insulin pumps and/or continuous glucose monitors, may be indicated to support insulin replacement therapy

Insulin Replacement in the Primary Care Setting: Practical, Case-based Considerations

  • Select appropriate design and implementation processes for basal/bolus insulin replacement therapy, which incorporate the role of newer insulins and treatment tools
  • Recognize and identify clinical scenarios where the use of newer technology, such as insulin pumps and/or continuous glucose monitors, may be indicated to support insulin replacement therapy
  • Identify methods to overcome patient and provider barriers to successful initiation and utilization of insulin replacement therapies, particularly in scenarios where new and evolving treatment tools may be leveraged to assist in doing so

Acknowledgement

This activity is supported by educational grants from Lilly, Novo Nordisk Inc., Medtronic, and MannKind. For further information concerning Lilly grant funding visit www.lillygrantoffice.com.

Tuition

Complimentary

Accreditation Statement

The activities have been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Joslin Diabetes Center and PlatformQ Health Education, LLC. Joslin Diabetes Center is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation Statements

Live Internet Activity

Joslin Diabetes Center designates this live activity for a maximum of 3.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activities.

Enduring Material

Joslin Diabetes Center designates this enduring material for a maximum of 3.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Date of Release/Expiration

Live Internet Activity

Wednesday, June 13, 2018, from 11:00 AM EST – 12:00 PM EST
• The Rapidly Evolving Options for Insulin Therapy: Clinically-Focused Pharmacology

Wednesday, July 18, 2018, from 12:00 PM EST – 2:00 PM EST
• 12:00 PM EST – 1:00 PM EST: Physiologic Insulin Replacement: Strategies for Non-Specialist Diabetes Care Providers
• 1:00 PM EST – 2:00 PM EST: Insulin Replacement in the Primary Care Setting: Practical, Case-based Considerations

Enduring Material

The enduring material will be available from June 13, 2018 – January 18, 2019.

Intended Audience

Primary audience: Primary care providers, including MDs, DOs, PAs and ANPs, and specialty providers, such as cardiologists and nephrologists, who provide care for people with diabetes.

Secondary audience: Endocrinologists/diabetologists, certified diabetes educators and pharmacists.

Method Of Participation

There are no fees to participate in this activity. To receive credit, participants must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the posttest and activity evaluation. It is estimated that this module will take approximately 3 hours to complete. To receive AMA PRA Category 1 Credit™, participants must receive a minimum score of 70% on the posttest.

Hardware/Software Requirements

Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.

Facutly

Richard S. Beaser, MD
Associate Professor of Medicine
Harvard Medical School
Senior Physician; Medical Director, Continuing Medical Education
Joslin Diabetes Center

Alissa R. Segal, PharmD, CDE, CDTC, FCCP
Professor of Pharmacy Practice
MCPHS University
Clinical Pharmacist
Joslin Diabetes Center

Jason Gaglia, MD, MMSc
Assistant Professor of Medicine
Harvard Medical School
Director of Hood Center for the Prevention of Childhood Diabetes
Joslin Diabetes Center

Mark E. Molitch, MD
Martha Leland Sherwin Professor of Endocrinology, Division of Endocrinology, Metabolism and Molecular Medicine
Northwestern University Feinberg School of Medicine

Faculty Disclosures

As part of its accreditation with the Accreditation Council for Continuing Medical Education, Joslin Diabetes Center must disclose to the audience of a Joslin continuing medical education activity the existence of any relevant financial relationships between Joslin and/or its planning and/or CME advisory committee members, speakers, and their spouses/partners and commercial entities. Joslin and its planning and CME advisory committee members and speakers must disclose any relationships they and their spouses/partners have or have had in the prior 12 months with proprietary entities producing healthcare goods or services, with the exception of nonprofit or government organizations and non-healthcare-related companies, which are exempt.

Financial relationships are those relationships in which the individual benefits by receiving a salary, royalty, intellectual property rights, consulting fees, honoraria, ownership interests (e.g., stocks, stock options, or other ownership interest, excluding diversified mutual funds), or other financial benefit in any amount. Financial benefits are usually associated with roles such as employment, management position, independent contractor (including contracted research), consulting, speaking and teaching, membership on advisory committees or review panels, board membership, and other activities from which remuneration is received or expected.

If a faculty or planning committee member has no information to disclose, this information will also be provided. If a faculty or planning committee member refuses to disclose, he/she will not be able to participate in the planning, management, presentation, or evaluation of any Joslin Diabetes Center CME activity. In addition, faculty have been asked to disclose when a product or device is not labeled for the use under discussion. The opinions and comments expressed in this program are those of the speakers and should not be considered the opinions or comments of Joslin Diabetes Center.

The faculty and planning committee members for this program have disclosed the following:
The planners and faculty have reported the following financial relationships with commercial interests. Via Joslin internal review, any relationship deemed relevant to the content of this activity has been identified and resolved through Joslin’s internal processes.

Financial Disclosures

Faculty

  • Dr. Richard S. Beaser*†, Senior Staff Physician and Medical Director of CME, Joslin Diabetes Center, has no relevant financial relationships with regard to this activity
  • Alissa Segal†, , PharmD, CDE, CDTC, FCCP, Professor of Pharmacy Practice, MCPHS University; Clinical Pharmacist, Joslin Diabetes Center, is a consultant for Lilly and Boehringer Ingelheim.
  • Mark E. Molitch, MD, Martha Leland Sherwin Professor of Endocrinology, Division of Endocrinology, Metabolism and Molecular Medicine, Northwestern University Feinberg School of Medicine, has received grant/research support from Novo Nordisk.
  • Jason Gaglia, MD, MMSc, Assistant Professor of Medicine, Harvard Medical School; Director of Hood Center for the Prevention of Childhood Diabetes, Joslin Diabetes Center, has no relevant financial relationships with regard to this activity.

Planning Committee

  • Joe Chebli, MD, Medical Director, PlatformQ Health Education, has no relevant financial relationships
  • Elizabeth del Nido, Program Manager, PlatformQ Health Education, has no relevant financial relationships

Joslin CME Advisory Committee

  • Jerry Cavallerano, OD, Optometrist, Beetham Eye Institute, Joslin Diabetes Center, has no relevant financial relationships.
  • Nuha El Sayed, MD, Staff Physician and Medical Director, Professional Education, Joslin Diabetes Center, has no relevant financial relationships.
  • Erin Kelly, CDE, Adult Diabetes Educator, Joslin Diabetes Center, is a contract pump trainer for Medtronic, Tandem, Omnipod and Animas.
  • Melinda Maryniuk, CDE, Director, Clinical Programs, Joslin Diabetes Center, has no relevant financial relationships.
  • Lyle Mitzner, MD, Staff Physician, Joslin Diabetes Center, is a consultant for Conversa Health
  • Kavita Seetharaman, MD, Staff Physician, Joslin Diabetes Center, has no relevant financial relationships
  • Alissa Segal, Pharm D, CDE, CDTC, FCCP, Clinical Pharmacist, Joslin Diabetes Center, is a consultant for Lilly and Boehringer Ingelheim.
  • Robert C. Stanton, MD, Chief of Nephrology, Joslin Diabetes Center, has no relevant financial relationships
  • Elena Toschi, MD, Staff Physician, Joslin Diabetes Center, has no relevant financial relationships.

* also on the Planning committee
† also on the CME Advisory Committee

Contact Information

Please send content inquiries to: CME@Joslin.harvard.edu

For technical problems with the site or issues with your CME Certificate, please contact DiabetesSeriesLive at 877-394-1306 or at Support@DiabetesSeriesLive.com.

DISCLAIMER

The material is prepared based on a review of multiple sources of information but is not exhaustive of the subject matter. Therefore, health care professionals and other individuals should review and consider other publications and materials about the subject matter other than relying solely on the information contained in this material.

The information presented at this CME program represents the views and opinions of the individual presenters, and does not constitute the opinion or endorsement of, or promotion by Joslin Diabetes Center, DiabetesSeriesLive, PlatformQ Health Education, LLC or the program grantor. Reasonable efforts have been made to present educational subject matter in a balanced, unbiased fashion and in compliance with regulatory requirements. Each participant must use his/her personal and professional judgment when considering further application of this information, particularly as it may relate to patient diagnostic or treatment decisions including, without limitation, FDA-approved uses and any off-label uses.